– Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options – – Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream – WAYNE, Pa., Nov. … Continue reading "Aclaris Therapeutics Initiates Phase 2b Trial of…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.